Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
AIN
ModerateOpen →
EGFR-MET bispecific antibody
Amivantamab
Rybrevant · Amiv
EGFR-MET bispecific antibody with class electrolyte wasting and an emerging interstitial-nephritis flag.
ModerateEGFR-MET bispecific antibody · approved 2021
EGFR exon 20 insertion NSCLCEGFR-mutant NSCLC (with lazertinib)
Signature kidney injury
Acute Interstitial Nephritis
In CHRYSALIS, electrolyte disturbance — notably hypokalemia (grade 3–4 in ~5%) and hypomagnesemia/hypocalcemia — was among the notable laboratory adverse events, consistent with EGFR-pathway inhibition. Acute interstitial nephritis is an emerging, clinician-flagged signal that is not yet quantified in the published renal literature.
Source: Park et al., J Clin Oncol 2021 (CHRYSALIS)
Mechanism of kidney injury
EGFR signaling drives the distal-convoluted-tubule magnesium channel TRPM6; EGFR blockade produces a mutated-TRPM6-like state with renal magnesium (and calcium) wasting, plus hypokalemia. This electrolyte syndrome is the established, mechanistic renal effect of EGFR-pathway inhibition. Separately, an emerging acute interstitial nephritis signal is presumed to be immune/hypersensitivity-mediated tubulointerstitial inflammation — biologically plausible given the antibody's Fc-effector and immune-directing activity — but drug-specific renal-biopsy data remain limited.
Clinical presentation
Hypomagnesemia, hypokalemia and hypocalcemia on labs (sometimes symptomatic — cramps, tetany, arrhythmia). With AIN: a subacute creatinine rise, sometimes with sterile pyuria, white-cell casts, low-grade tubular proteinuria and occasionally eosinophilia/eosinophiluria. Infusion-related reactions are common with the first dose (non-renal).
Onset
Electrolyte changes during therapy and cumulative; AIN timing not well characterized (subacute, days–weeks after a triggering exposure by analogy to drug AIN).
Reversibility
Variable
Anticancer mechanism
EGFR-MET bispecific IgG1 antibody that binds the extracellular domains of both receptors, blocking ligand binding, promoting receptor internalization/degradation, and engaging Fc-mediated effector function (antibody-dependent cellular cytotoxicity/trogocytosis) — bypassing kinase-domain resistance. Approved for EGFR exon 20 insertion NSCLC and, with lazertinib, broader EGFR-mutant (exon 19 del/L858R) NSCLC.
Management
Aggressive repletion of magnesium, potassium and calcium (oral often insufficient — IV magnesium frequently required). For suspected AIN: hold the drug, exclude alternative causes, and consider corticosteroids per onconephrology guidance, ideally with biopsy confirmation when feasible.
Risk factors
- Concurrent EGFR TKI (combination with lazertinib)
- Other nephrotoxins or AIN-associated drugs (PPIs, NSAIDs)
- Pre-existing CKD
- Baseline electrolyte depletion
Prevention
- Monitor electrolytes (especially magnesium) and creatinine on therapy
- Pre-emptive potassium/magnesium repletion
- Review concomitant AIN-associated drugs
- Early nephrology input for an unexplained creatinine rise
Note · AIN is a newly recognized, clinician-flagged signal with thin published renal literature; characterization here is deliberately conservative and class-/case-based. The reliable, mechanism-anchored renal effect is EGFR-mediated electrolyte (magnesium) wasting.
Clinical depth
Renal dose adjustment
No established renal dose adjustment (monoclonal antibody, not renally cleared). Manage by electrolyte repletion and infusion-rate modification; hold for suspected AIN rather than dose-reduce.
Dialyzability & ESKD dosing
Large IgG bispecific antibody — not dialyzable and cleared by reticuloendothelial proteolysis; no ESKD dose change expected. Electrolyte management is the renal priority in advanced CKD.
Differential diagnosis
EGFR-mediated electrolyte wasting (Mg/K/Ca low, bland sediment) vs antibody-related AIN (rising creatinine, pyuria/WBC casts, possible eosinophiluria) vs pre-renal AKI from diarrhea/poor intake; cystatin C can clarify true GFR if creatinine interpretation is uncertain. Co-administered lazertinib adds its own hyponatremia signal.
Monitoring
- Serum magnesium, potassium and calcium each cycle (and repletion to keep ahead)
- Serum creatinine each cycle
- Urinalysis if creatinine rises (pyuria/casts to flag AIN)
Key trials & series
- CHRYSALIS (Park JCO 2021) — pivotal exon 20 data with hypokalemia
- MARIPOSA (amivantamab + lazertinib vs osimertinib) — combination toxicity context
- PAPILLON (with chemotherapy) — frontline exon 20
Clinical pearls
- Expect magnesium wasting: EGFR blockade disables distal-tubular TRPM6 — replete proactively, often with IV magnesium.
- AIN is an emerging, ASON-flagged signal — a creatinine rise with sterile pyuria/casts should trigger drug-hold and nephrology referral, not just dose-reduction.
- It is an antibody — no renal dosing and no dialysis removal; ESKD management is electrolyte- and AIN-focused.
- In combination with lazertinib, watch sodium too — overlapping EGFR-class electrolyte effects.
Where it strikes
Nephron segments
Interstitium
Supporting tissue around the tubules
Injury signatures
Acute Interstitial NephritisElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of egfr-met bispecific antibodys.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Acneiform rash, paronychia
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Interstitial lung disease (EGFR TKIs)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkAmivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.Park K et al. · J Clin Oncol 2021 · PMID 34339292Pivotal trial documenting hypokalemia (grade 3–4 ~5%) and the overall safety profile.PMIDAdverse kidney effects of epidermal growth factor receptor inhibitors.Izzedine H et al. · Nephrol Dial Transplant 2017 · PMID 28339780Onconephrology review of EGFR-inhibitor dual renal toxicity — tubular/electrolyte disorders and glomerulopathy — the mechanistic basis for amivantamab's renal effects.PMIDHypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents.Costa A et al. · Target Oncol 2011 · PMID 22113391Explains EGFR-blockade–induced TRPM6 dysfunction causing renal magnesium/calcium wasting — the dominant electrolyte mechanism.PMIDRenal Side Effects of Novel Molecular Targeted Oncologic Agents.Fenoglio R et al. · G Ital Nefrol 2023 · PMID 38007829Biopsy series of targeted-therapy renal injury showing tubulointerstitial nephritis and TMA — supports vigilance for antibody-associated AIN.PMIDThe changing treatment landscape of EGFR-mutant non-small-cell lung cancer.Zhou F et al. · Nat Rev Clin Oncol 2024 · PMID 39614090Review of amivantamab's mechanism and role in EGFR-mutant NSCLC.PMIDAmivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Felip E et al. · Ann Oncol 2024 · PMID 38942080Combination context (amivantamab + lazertinib) reflecting current use and overlapping electrolyte toxicity.